Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Tarceva

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tarceva was produced by Roche and Astellas.

AZ starts pursuit of lung cancer indication for Imfinzi

AZ starts pursuit of lung cancer indication for Imfinzi In that study, patients on Tagrisso had a PFS of 18.9 months, compared to just over 10 months for first-generation EGFR-targeting drugs, Roche's Tarceva (erlotinib) and

AZ buoyed by latest lung cancer data at ESMO

AZ buoyed by latest lung cancer data at ESMO to just over 10 months for first-generation EGFR-targeting drugs, Roche's Tarceva (erlotinib) and AZ's own Iressa (gefitinib).

AZ gets rapid approval in China for Tagrisso

AZ gets rapid approval in China for Tagrisso Moreover, nearly two thirds patients whose disease progresses after treatment with a first-line EGFR inhibitor - such as Iressa, Roche/Astellas' $2bn-a-year Tarceva (erlotinib) and Boehringer Ingelheim's Giotrif

Novocure’s chief commercial officer to step down

Novocure’s chief commercial officer to step down Previously, he was senior vice president for sales and marketing at OSI Pharmaceuticals, where he led the global commercialisation of Tarceva (erlotinib) from 2003 to 2011.

AZ's Tagrisso beats chemotherapy in lung cancer trial

AZ's Tagrisso beats chemotherapy in lung cancer trial The mutation develops in around two-thirds of patients who have received other EGFR inhibitors, such as Roche/Astellas' $2bn-a-year Tarceva (erlotinib), AstraZeneca's Iressa (gefitinib) and Boehringer

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics